The oral maxillofacial bone is a site of predilection for tumors, inﬂammation, trauma, and congenital disease that are usually treated by surgical operations, and surgical site infections represent second-most common hospital-acquired infections. Therefore, the overall goal of the proposed MATRI-X project is to develop controllable clindamycin and autologous growth factor delivery systems on the basis of marine polysaccharides and autologous platelet rich fibrin (PRF) matrice, simultaneously ensuring prophylactic antibiotic treatment and promoted tissue regeneration. The novel clindamycin and growth factor sustained delivery system will be designed on PRF and self-assembling fucoidan and chitosan microgels/particles (starting from TRL2 and ending up to TRL4). Physicochemical properties and antibacterial activity against isolated bacteria from clinical specimens will be investigated. Results will be summarized in high impact Open Access publications and presented at international conferences. The research proposal match with the Priority Directions in Science in Latvia, such as Public Health. The research results have a potential for transfer from laboratory to the market as high added value biomedical products. Thus, they can give a beneficial impact on the Latvian national economy as well as public health sector and promote a development of sustainable modern healthcare system by improvement of the quality of life of patients who suffer from tissue defects and disorders.
|Effective start/end date||1/01/21 → 31/12/23|
- Oral and maxillofacial surgery
- drug delivery
- autologous systems
Field of Science
- 3.1 Basic medicine
Smart Specialization Area
- Biomedicine, medical technologies and biotechnology
- Smart materials, technology and engineering
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.